Key Takeaways & Executive Findings
- •• 3D bioprinting enables precise construction of muscle-tendon interface mechanical transition layers and tendon-bone interface four-zone gradient structures through patient imaging and computer-aided design. • Multiple 3D printing techniques (e.g., extrusion-based, fused deposition modeling, laser-assisted) are applied to fabricate biomimetic scaffolds, offering trade-offs between resolution, speed, and cell viability. • Functionalized bioinks and multi-technology synergy enhance scaffold bioactivity and mechanical-biological coupling, enabling full-cycle intervention from inflammation to remodeling. • Despite progress, challenges remain including resolution-efficiency trade-offs, shear-induced cell damage, material degradation mismatch, and insufficient long-term safety data, hindering clinical translation.
Abstract
BACKGROUND: Currently, three-dimensional (3D) bioprinting technology, with its controllable multi-scale structure and functional integration design capabilities, has become a cutting-edge solution for tendon tissue engineering. OBJECTIVE: To systematically summarize the latest research progress of 3D bioprinting technology in tendon repair. METHODS: Using the keywords “3D printing, bioink, myotendinous junction, tendon repair, tendon-bone junction, bionic scaffold,” literature searches were conducted in the PubMed and Web of Science databases, as well as in the China National Knowledge Infrastructure (CNKI) with the same keywords. Articles with weak relevance to the topic were excluded, and 109 articles were ultimately included for review. RESULTS AND CONCLUSION: 3D bioprinting technology, through multi-material integration and controllable biomimetic structural design, effectively reproduces the multi-level structure of tendons. Mainstream technologies (such as melt electrowriting, extrusion-based printing, etc.) play differentiated advantages in fiber alignment, interface simulation, and dynamic regulation, constructing mechanical transition layers at the muscle-tendon interface and four-zone gradient structures at the tendon-bone interface. Functionalized bioink innovations (immunomodulatory materials, cross-species oxygen-supplying scaffolds, etc.) and multi-technology synergy (aligned fiber deposition + photocuring reinforcement) enhance scaffold bioactivity and mechanical-biological coupling. In the full healing cycle (support in the inflammatory phase, guidance in the proliferative phase, regulation in the remodeling phase), precise intervention from molecular to macroscopic levels is achieved, optimizing collagen alignment and repair mechanical properties. Differentiated repair strategies (multi-material gradients, aligned fibers, gradient scaffolds) for the muscle-tendon interface, tendon body, and tendon-bone interface have made progress. Despite challenges such as resolution-efficiency contradictions and insufficient material matching, 3D printing technology still provides new strategies for tendon repair from structural biomimicry to functional regeneration. In the future, the integration of intelligent materials (photothermal/piezoelectric) and multimodal technologies (4D printing, organoids) is expected to promote dynamic functional regeneration and provide technical references for interface repair.
1. Introduction
Tendons, as core mechanical transmission structures connecting muscle to bone, directly influence the precision and stability of limb movement. Natural tendons exhibit excellent tensile properties through highly aligned multi-level collagen fibers (from nano-fibrils to macroscopic fiber bundles), and rely on the elastic transition at the myotendinous junction and the four-zone gradient structure at the tendon-bone interface (collagen type transitions from type I to type II and type X, with progressive mineralization) to achieve soft-to-hard tissue mechanical adaptation, ensuring efficient transmission of movement loads. However, the low cell density, avascular nature, and defective regenerative microenvironment (e.g., stem cell deficiency, inflammatory imbalance) severely limit tendon regeneration capacity—clinical functional recovery rates are only 60%-70%, and the risk of re-injury is significantly increased. Moreover, the myotendinous and tendon-bone interfaces often form fibrous scars due to mechanical mismatch, further exacerbating functional impairment.
Traditional repair techniques such as suturing and autograft/allograft transplantation can restore anatomical continuity but fail to reconstruct the biomimetic mechanical transmission pathway of tendons: suturing is prone to re-rupture due to stress concentration, while transplantation faces issues of limited donor availability, immune rejection, and poor interface integration, all of which cannot effectively address the heterogeneous repair challenges at the myotendinous and tendon-bone interfaces. In recent years, 3D printing technology, with its unique advantages of multi-material integration, controllable structural biomimicry, and dynamic biological regulation, has provided breakthrough strategies for tendon repair. By integrating patient imaging data with computer-aided design, 3D printing can precisely construct mechanical transition layers at the myotendinous junction and four-zone gradient structures at the tendon-bone interface. Combined with functionalized bioink innovations (e.g., immunomodulatory materials, cross-species oxygen-supplying scaffolds) and multi-technology synergy (e.g., extrusion-based aligned fiber deposition with photocuring reinforcement), it enables full-cycle intervention from inflammatory phase support, proliferative phase guidance, to remodeling phase regulation, significantly optimizing collagen alignment and repair mechanical properties. Although 3D printing technology has shown significant potential, it still faces technical bottlenecks and clinical translation challenges: mainstream technologies exhibit resolution-efficiency contradictions, shear forces easily cause cell damage, and material degradation does not match mechanical requirements. Additionally, research is mostly laboratory-based, lacking long-term safety data, and the synergistic study of complex biological processes such as neurovascular regeneration is insufficient.
Loading authentic research manuscript (Pages 1–5)...
LIU Xuemiao, ZHANG Yuchang, ZHANG Weiguo, TIAN Kang, WANG Xing (2026). Three-dimensional bioprinting and tendon repair: application advances and future directions. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21469
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the main challenges of 3D bioprinting for tendon repair?
Main challenges include resolution-efficiency trade-offs, shear-induced cell damage, material degradation mismatch with mechanical needs, and lack of long-term safety data for clinical translation.
How does 3D bioprinting address the complexity of tendon-bone interface repair?
3D bioprinting can create four-zone gradient structures with collagen type transitions and mineralization gradients, mimicking the native interface and promoting functional integration.
What are the key technologies used in 3D bioprinting for tendons?
Key technologies include extrusion-based printing, melt electrowriting, fused deposition modeling, and laser-assisted bioprinting, each offering different advantages in resolution, speed, and cell viability.
What future directions are suggested for 3D bioprinting in tendon repair?
Future directions include integrating intelligent materials (photothermal/piezoelectric) and multimodal technologies (4D printing, organoids) to achieve dynamic functional regeneration and improve clinical outcomes.
What is the significance of bioink functionalization in tendon repair?
Functionalized bioinks, such as immunomodulatory materials and oxygen-supplying scaffolds, enhance scaffold bioactivity and support the healing process by modulating the immune environment and promoting cell survival.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.